Edit

Voyager Therapeutics

http://www.voyagertherapeutics.com/

Last activity: 19.09.2025

Active

Categories: BioTechDeliveryEngineeringFinTechHumanManufacturingPlatformResearch

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases.

Contact:
Voyager Therapeutics
75 Sidney St.
Cambridge, MA 02139
info@voyagertherapeutics.com
857-259-5340

Followers

849

Followers

22.5K

Mentions

Employees: 201-500

Total raised: $105M

Founded date: 2014

Twitter

Investors 2

Date	Name	Website
-	PFM Health...	pfmhealths...
13.07.2025	Foresite C...	foresiteca...

Funding Rounds 2

Date	Series	Amount	Investors
13.04.2015	Series B	$60M	-
12.02.2014	Series A	$45M	-

Mentions in press and media 22

Date	Title	Description
19.09.2025	T.Rx Capital: $77.5 Million Fund I Launched To Invest In Startups	T.Rx Capital, a newly formed venture capital firm dedicated to early-stage healthcare innovation, has announced the close of its first fund, T.Rx Capital Fund I, at $77.5 million. The fund is focused on supporting visionary founders who are...
31.05.2025	Vima Therapeutics: $60 Million Series A Secured For Advancing Oral Therapy For People With Dystonia And Movement Disorders	Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing led by Atlas Venture, with participation from Access Industries and Canaan. Vima ...
13.03.2024	Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer	-
11.12.2021	Voyager Therapeutics : Corporate Presentation	UNLOCKING THE POTENTIAL OF AAV GENE THERAPY Corporate Presentation \| December 2021 © Voyager Therapeutics Forw ard-Loo king Statements This presentation, posted to the Company's website on December 10, 2021, contains forward -looking statem...
06.10.2021	Voyager Therapeutics’ strategy shift to gene therapy tech leads to a Pfizer alliance	With its lead gene therapy programs stalled by a series of setbacks, Voyager Therapeutics has been talking for months about refocusing its business on internal technology that finds capsids—the protein shells that envelope a gene therapy an...
04.08.2020	AbbVie shrugs off $134M cash deals, quitting a neuro R&D pact with Voyager Therapeutics on vectorized antibody treatments	It’s the end of the road for Voyager Therapeutics’ collaboration with AbbVie on tau and alpha-synuclein vectorized antibody development. In two deals spanning the last two years, AbbVie dropped more than $134 million...
17.06.2019	Sanofi, Voyager Therapeutics rejig gene therapy partnership	Shares of Voyager were up 14 percent on the Nasdaq late Monday morning following the news. Shares of Sanofi were down slightly on the Euronext Paris exchange. Under the restructured relationship, Voyager takes worldwide rights to VY-HTT01, ...
27.03.2019	Prevail Therapeutics raises $50M for gene therapy in Parkinson’s, other neurodegenerative disorders	According to its website, the company’s focus is on developing adeno-associated viral vector-based gene therapies for diseases like Parkinson’s disease. Its hypothesis is that by restoring healthy lysosomal function to the cells of a patien...
11.06.2018	Pharma giants like Novartis, Pfizer, and Sanofi are getting serious about a cutting edge therapy that changes human genes	AP Photo/Eric Risberg In this photo taken Monday, Nov. 13, 2017, nurse practitioner Jacqueline Madden prepares to start the first human gene editing therapy at the UCSF Benioff Children's Hospital in Oakland, Calif. Brian Madeux, 44, receiv...
06.09.2017	News of Note—Sarepta, Verastem and Voyager clock data win, shares boost	> Sarepta Therapeutics saw its shares jump 13% in early morning trading on new phase 1/2 data from its next-gen DMD candidate golodirsen. The medication hit its primary and secondary endpoints in 25 boys with confirmed deletions of the D...
29.06.2016	The biotech IPO feast flags as investors lose their appetite for R&D risk	There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund...
11.11.2015	$172M in IPOs from Wave Life Sciences, Voyager Therapeutics	Wave, a Harvard spinout, is using synthetic chemistry to develop a pipeline of nucleic acid therapeutics – developing stereopure treatments for Huntington’s disease and Duchenne muscular dystrophy that are expected to enter clinical develop...
13.04.2015	Voyager Therapeutics Completes $60M Series B Financing	Voyager Therapeutics, a Cambridge, Mass.-based gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), completed a $60m Series B financing. The round was co-led by ne...
13.04.2015	Cambridge gene therapy startup Voyager Therapeutics raises $60M for CNS disorders	Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermin...
11.02.2015	Voyager Therapeutics Grabs $30M Investment	CAMBRIDGE, MA, Gene therapy company announced a major strategic collaboration and investment. >> Click here for more funding data on Voyager Therapeutics >> To export Voyager Therapeutics funding data to PDF and Excel, click...
12.02.2014	Voyager Therapeutics Launches with $45M in Series A Financing	Voyager Therapeutics, a Cambridge, Mass.-based newly formed gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), launched with $45m in Series A financing. Third Ro...
12.02.2014	Voyager Therapeutics Launches with $45M in Series A	CAMBRIDGE, MA, Third Rock Ventures announced the formation of Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), with a $45 million Ser...
-	Sanofi, Voyager Therapeutics rejig gene therapy partnership	A gene therapy developer is making big changes to its four-year-old partnership with a large French drugmaker. Cambridge, Massachusetts-based Voyager Therapeutics said Monday it would restructure a partnership it started with Sanofi Genzyme...
-	Voyager Therapeutics’ strategy shift to gene therapy tech leads to a Pfizer alliance	With its lead gene therapy programs stalled by a series of setbacks, Voyager Therapeutics has been talking for months about refocusing its business on internal technology that finds capsids—the protein shells that envelope a gene therapy an...
-	$172M in IPOs from Wave Life Sciences, Voyager Therapeutics	Cambridge biotechnology company Voyager Therapeutics hit the market with a slightly downsized $70 million initial public offering. The company sold 5 million shares priced at $14 apiece; just a hair lower than the projected $15 to $17 per s...
-	Cambridge gene therapy startup Voyager Therapeutics raises $60M for CNS disorders	Cambridge gene therapy startup Voyager Therapeutics just wrapped up a $60 million Series B round to advance its treatments for conditions of the CNS like ALS and Parkinson’s disease. Voyager is using the money to advance its five clinical a...
-	Prevail Therapeutics raises $50M for gene therapy in Parkinson’s, other neurodegenerative disorders	A company developing gene therapies for neurodegenerative diseases has closed a round of financing that it hopes will bring it into clinical development. New York-based Prevail Therapeutics said Wednesday that it had raised $50 million in a...

Voyager Therapeutics

Investors 2

Funding Rounds 2

Mentions in press and media 22

Reviews 0